Fulgent Genetics (FLGT) Total Non-Current Liabilities (2016 - 2026)

Fulgent Genetics has reported Total Non-Current Liabilities for 11 years, with the latest figure at $84.3 million in Q2 2026.

• Quarterly Total Non-Current Liabilities rose 2.39% year-over-year to $84.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $84.3 million (up 2.39% YoY) and the FY2025 annual result came in at $99.2 million, up 18.32% from the prior year.
• Total Non-Current Liabilities eased to $84.3 million in Q2 2026 per FLGT's latest filing, from $102.8 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $142.9 million in Q1 2022 and troughed at $74.7 million in Q2 2023.
• A 5-year average of $93.9 million and a median of $88.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities sank 42.24% in 2023, then surged 33.82% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $97.9 million in 2022, then decreased by 11.22% to $87.0 million in 2023, then dropped by 3.59% to $83.8 million in 2024, then climbed by 18.32% to $99.2 million in 2025, then retreated by 15.04% to $84.3 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $84.3 million, $102.8 million, and $99.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.